An interventional study of AI in Lung Cancer, Artificial Intelligence (AI) and Randomized Controlled Trial, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-26.
Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University — 20 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · The First Affiliated Hospital of Guangzhou Medical University.
Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, this one is the 4th largest by planned enrollment of the 18 interventional ones that give a count, is one of 6 that started in 2024, is one of 12 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 13th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →20 of the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University are open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–80
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 40–74 · Healthy volunteers
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 40 Years to 74 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 7,294 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 110 across the 18 interventional studies, 550 across the 8 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The First Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 167 studies on the registry; 69 are open to participants now.
7 of the studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07150416The First Affiliated Hospital of Guangzhou Medical UniversityNebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study | 2026-12-01 |
| NCT06778512The First Affiliated Hospital of Guangzhou Medical UniversityLcProt: Proteomics Longitudinal Cohort Study on Lung Cancer | 2026-12-01 |
| NCT06422637The First Affiliated Hospital of Guangzhou Medical UniversityA Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy | 2026-12-01 |
| NCT06843707The First Affiliated Hospital of Guangzhou Medical UniversityEstablishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics. | 2026-12-31 |
| NCT07303881The First Affiliated Hospital of Guangzhou Medical UniversityGolidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
AI diagnostic systems show great promise for improving lung cancer screening in community healthcare settings. While not originally designed for primary care, these tools demonstrate capabilities in nodule detection and workflow optimization. However, their effectiveness in resource-limited community centers requires thorough evaluation.
This RCT compares AI-assisted versus manual CT interpretation across community health centers. Expert radiologists will establish reference standards, while an independent committee blindly evaluates cases from both groups. The study assesses diagnostic accuracy, operational efficiency, and cost-effectiveness, with blinded analysts resolving discrepancies through consensus to ensure reliable results.
Artificial intelligence (AI) technologies, particularly advanced medical imaging analysis systems like the AI diagnostic platform evaluated in this study, demonstrate significant potential for enhancing lung cancer screening programs in community healthcare settings.Although this AI system was not originally designed specifically for primary care implementation, it has shown promising capabilities in various clinical applications, including nodule detection, malignancy risk stratification, and workflow optimization in radiology departments. However, its effectiveness in improving screening accuracy and operational efficiency in resource-limited community health centers remains to be thoroughly investigated.
Lung cancer screening and diagnosis involve complex clinical processes,including image interpretation, risk factor assessment, and follow-up decision-making. Implementing AI tools like this diagnostic platform in community screening programs could potentially improve detection rates, standardize interpretations, and optimize resource allocation. Nevertheless, the system has not been rigorously validated for use in primary care settings and may carry limitations in generalizability across diverse patient populations and imaging equipment variations. Inappropriate implementation could lead to diagnostic errors or inefficient resource utilization. Therefore, evaluating how such AI systems can effectively support community-based screening while maintaining diagnostic accuracy and cost-effectiveness is of paramount importance.
In this randomized controlled trial, participating community health centers will be allocated to either an AI-assisted interpretation group or a conventional manual interpretation group. All screening cases will undergo standardized low-dose CT imaging, with results interpreted through the respective group's designated method. A panel of three expert radiologists will establish reference standards for all cases, while an independent review committee will blindly evaluate a subset of cases from both groups to assess interpretation consistency. The evaluation will focus on diagnostic performance metrics, operational efficiency parameters, and cost-effectiveness indicators. Two separate analyst teams, blinded to group assignments, will process and compare the outcomes using predefined statistical methods, with any discrepancies resolved through consensus discussions to ensure data reliability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The AI-assisted group utilized AI-powered diagnostic software for interpreting low-dose computed tomography (LDCT) scans
Other: AI
The manual interpretation group relied on standard radiologist evaluation for analyzing low-dose computed tomography (LDCT) scans.
An integrated AI-human collaborative workflow for lung cancer screening interpretation
Diagnostic Accuracy
Sensitivity and Specificity: Comparison of AI-assisted versus manual interpretation in detecting malignant pulmonary nodules, validated against histopathological confirmation or 12-month clinical follow-up. Early Detection Rate: Proportion of stage I/II lung cancers correctly identified by each method.
Time frame: One year after entry
Interpretation Consistency
Inter-reader Agreement: Measured by Cohen's kappa (κ) between AI-assisted radiologists and the independent review committee (IRC). Intra-reader Variability: Consistency of nodule classification in repeat readings (subset analysis).
Time frame: One year after entry
Cost-Effectiveness
Resource Utilization: Comparative analysis of staffing, equipment, and follow-up costs per detected cancer case. Incremental Cost per QALY (Quality-Adjusted Life Year): Long-term economic impact modeling.
Time frame: One year after entry
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Oct 2025, 15 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 15 months is below that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Guangzhou Medical University →